ArticleBlood advances2023
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase I
In one paragraph
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06703216 (Pilot Study of Pre-emptive Anakinra for the Prevention of Severe Cytokine Release Syndrome in Children and Young Adults With B-Acute Lymphoblastic Leukemia Receiving Chimeric Antigen Receptor), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06703216 phase1 / phase2withdrawnnot on this mapstarted 2026, after this paper: background citation
Pilot Study of Pre-emptive Anakinra for the Prevention of Severe Cytokine Release Syndrome in Children and Young Adults With B-Acute Lymphoblastic Leukemia Receiving Chimeric Antigen Receptor (CAR) T Cells
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2024Guideline
- Safety and Pharmacokinetics of SRN001, a Novel siRNA Drug Targeting Amphiregulin via the SAMiRNA Platform.Drug design, development and therapy · 2026Trial
- Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.Blood advances · 2025Trial
- CRS and ICANS: Early detection and personalized management.Blood research · 2026Review
- ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.Haematologica · 2026Article
- The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology · 2026Review
- Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers.Transplantation and cellular therapy · 2026Article
- Neurological implications of chimeric antigen receptor-T cell therapy.BMJ neurology open · 2026Review
- The clinical picture of ICANS after CAR-T cell therapy in critically ill patients: A retrospective clustering analysis of a multicentre multinational cohort study.Annals of intensive care · 2026Article
- Knowledge mapping and visualized analysis of research progress in onconephrology: a bibliometric analysis.Renal failure · 2025Article
- Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.Journal for immunotherapy of cancer · 2025Article
- Neurological complications of CAR T cell therapy for cancers.Nature reviews. Neurology · 2025Review
- Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.Transplantation and cellular therapy · 2025Article
- Noncanonical and mortality-defining toxicities of CAR T cell therapy.Nature medicine · 2025Review
- Novel strategies to manage CAR-T cell toxicity.Nature reviews. Drug discovery · 2025Review
- EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapy.Journal of neurology · 2025Article
- Multi-array Technology for Secreted Cytokine Profiling in a Nano-aerosol Exposed 3D Human Alveolar Cell Model.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Toxicity of CAR T-Cell Therapy for Multiple Myeloma.Acta haematologica · 2025Review
- Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy.Journal for immunotherapy of cancer · 2024Article
- Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes.Open forum infectious diseases · 2024Article
Corrections and comments
- Commented on by
Authors and funding
28 authors at 1 institution in 1 country.
Paolo StratiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Andrew JalloukDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4335-7942
Qing DengDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Xubin LiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ryan SunDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1176-1561
Sherry AdkinsDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Swapna JohncyDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9178-3642
Taylor CainDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Raphael E SteinerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sairah AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7302-8299
Dai ChiharaDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1153-2294
Luis E FayadDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Swaminathan P IyerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1646-813X
Sandra HorowitzDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Loretta J NastoupilDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6071-8610
Ranjit NairDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ahmed HassanDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Taher E DaoudDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Misha HawkinsDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Maria A RodriguezDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-3564-8697
Elizabeth J ShpallDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jeremy L RamdialDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
Partow KebriaeiDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
David S HongDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jason R WestinDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1824-2337
Sattva S NeelapuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1045-4914
Michael R GreenDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTargeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell LymphomaR21CA259694 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GREEN, MICHAEL RICHARD, STRATI, PAOLO · 2021 to 2021
$379kNCI NIH HHS P30 CA016672NCI NIH HHS R21 CA259694
Abstract
PubMed holds no abstract for this paper.
Indexed as
Interleukin 1 Receptor Antagonist ProteinLymphoma, Large B-Cell, DiffuseHumansImmunotherapy, AdoptiveInterleukin 1 Receptor Antagonist Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT06703216ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.